Eli Lilly and Company closed at $1,138.21 on September 17, 2026, a gain of 0.11% over the prior 24-hour period. The pharmaceutical giant's market capitalization stood at $1,012.68 billion, keeping the company among a narrow group of U.S. equities valued above the $1 trillion threshold.
Over the trailing seven days, LLY shares advanced 1.26%, suggesting some stabilization after a more difficult stretch. The stock's 30-day performance tells a different story, however, with shares down 3.94% over that period, reflecting selling pressure that has weighed on the name in recent weeks.
The single-day gain was marginal in absolute terms, but the seven-day trend indicates buyers have been returning to the stock following the broader monthly pullback. The current price of $1,138.21 reflects the net result of those competing forces across different time horizons.
No single catalyst was identified in the available data to account for the day's movement. The figures indicate LLY remains a closely watched large-cap stock, with its trillion-dollar valuation continuing to draw attention from market observers tracking the pharmaceutical sector.
